Umbra Applied Technologies Group Inc (UATG)

[Babubd]

Quietly accumulating for a REASON! Big Things are Brewing Behind the Scenes!! FDA Approval will send here to MOON!!

Like Rick Rule Says - market may stay irrational for some time and then a VIOLENT KABOOOOOM takes place and within a short period of time it is gone trading in a different stratosphere. Same will happen with UATG 100%.

Folks, OS is JUST 971.34 Million including 75.968 million restricted shares. Tech stock with such a low OS in OTC and biotech, clean energy and defense & security sector, PPS @ $0.50..$0.75..$1..$2..$5++..??, anything is possible.
https://www.otcmarkets.com/stock/UATG/security

Shorts are screwed up here. Total Shorted Volume is 35.897 Million. Huge Short Squeeze is imminent. Shorts are gonna be scrambling, weeping and biting their nails.
https://marketwirenews.com/stock/uatg/short/

Let's go UATG and hit Dollar Land!!

Know What You Own:

UAT Group CEO's Recent Presentations on Corporate Strategy:
Nov. 5, 2021, Nov. 2, 2021 and Oct. 23, 2021

https://www.youtube.com/watch?v=ZeUcwAXYUJY

https://www.youtube.com/watch?v=392CcTvzBRU

https://www.youtube.com/watch?v=zdiNZcngw6Q

UAT Group Subsidiary, H2O Processing Forms Joint Venture Company with Texas Strategic Partner

Denver, CO, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Umbra Applied Technologies Group, Inc (OTC Pink: UATG) subsidiary, H2O Processing, Inc., an advanced water treatment technology company, announced today that it has formed a new joint venture company with its strategic partner Precision Process Design and Mechanical, Inc (PPD&M Inc), a Texas based water filtration technology company. The new company, H2O Process Engineering, LLC, a Colorado based Limited Liability Company, will be equally owned and managed by the two strategic partners.

H2O Processing Chief Executive Officer, Stan Abrams stated, “This new partnership will combine the best that both companies have to offer under one roof so that we can treat a wider selection of contaminated water”.

The new company will benefit from proprietary technologies owned by both parent companies and will service a full range of water treatment needs that are currently either not available or cost-effective based on existing technologies in the oil and gas sector. The new joint venture is currently targeting the Marcellus Shale region in the United States. The Marcellus Shale runs across the Southern Tier and Finger Lakes regions of New York, in northern and western Pennsylvania, eastern Ohio, through western Maryland, and throughout most of West Virginia.

PPD&M, Inc Chief Executive Officer, Farid Gozashti stated, “H2O Processing Engineering is the culmination of decades of experience and delivers advanced proprietary technologies within a one-stop firm. We will now be able to treat water that until now has either been impossible or not realistic from a cost perspective”.

H2O Processing Engineering is currently compiling its joint technologies and will begin the process of filing additional patents on two of its new technologies, a high-performance filter (HF) and new evaporator unit that will expand the company’s capabilities so that it can treat various water mediums regardless of total dissolved solids count or particulate matter contained therein. These new technologies carry with them the potential to save existing oil companies millions of dollars a day in water discharge and treatment costs.

Chairman of H2O Processing parent company, UAT Group, Alex Umbra commented, “This new company will not only ameliorate the environmentally impact of existing fracking and/or drilling operations, it will make such efforts more cost-effective to do so. With fuel prices on the rise, these new technologies will help to reduce operational costs so that a savings can be passed on to consumers. The cost savings to existing operators is that significant”.

Oil companies currently operating in this region typically produce 250,000 barrels a day of wastewater that needs to be treated or disposed of. Current estimates to dispose of wastewater start around $9-$11/barrel and exceed as much as $40/barrel. H2O Processing Engineering estimates that it can treat and return water for use back to the operators at a cost savings of 70%. With such a dramatic cost savings unrivaled in the industry, the new joint venture will be poised to save oil companies millions of dollars daily.

The new joint venture anticipates potential six-figure revenues per operational day, with year one estimates reaching eight figures. The company will be releasing guidance for years 1-3 in the coming months, as well as environmental impact savings per region, once operational.

H2O Processing, Inc Chief Operating Officer, Brett Abrams said, “This technology not only delivers an operational cost savings, it also delivers a more environmentally friendly process of treating water that reduces the impact to the surrounding areas”.

For more information about H2O Processing, Inc. visit: https://h2oprocessing.com/

For more information, visit www.uatgroup.com

Investor and Media Contact: UAT Group at [e-mail]

About H2O Processing, Inc.

The company is located in Denver, CO and is an advanced water treatment technology company.
https://ca.finance.yahoo.com/news/uat-group-subsidiary-h2o-processing-120000122.html

UAT Group Strategic Partner NextCast Receives Patent Approval

Tampa, FL, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Umbra Applied Technologies Group, Inc (OTC Pink: UATG) (“UAT Group”) announced today that strategic partner Next Casting Technologies has received its Notice of Allowance from the United States Patent Office, paving the way for its advanced SmartCast, IntelliBrace and BioSplint technology to enter into patented production.

UAT Chief Executive Officer Alex Umbra, stated, “The NextCast SmartCast system has been under development and testing for quite some time. This is the final step of a lengthy patent process before entering the production phase of these product lines.”

Next Casting Technologies (NCT) is a research and design-centric, biomedical technology company, with an expanding portfolio of intellectual property. The SmartCast Application allows the casting technician to slip the SmartCast around the affected limb and position to ?t by using a simple “mold and hold” technique. Lastly, the cast is activated by pressing the button to initiate the curing process. Within 4 minutes that cast is hardened, fixed in place and is not dependent on the technician’s artistry, or lack thereof. The results are a predictable standard of care across the patient spectrum. The end result is a completely waterproof, antimicrobial, orthopedic cast, that is time saving for clinicians and a superior standard of care for patients.

Mark Estrada, Chief Executive Officer of NextCast commented, “This is what we have been waiting for. We initially filed with an expanded overview of the technology to include casting, bracing and splinting. Now that the United States Patent Office has approved this outline we can proceed with continuing claims. I am excited to move forward to the production phase of this new and exciting product line”.

The company anticipates beginning production of the SmartCast product line and sharing the technology via our updated web site in the coming weeks with revenues being reported on its financial statements in Q1 2022.

For more information about NextCast go here: https://nextorthocast.com/

For more information about UAT go here: http://umbraappliedtechnologies.com/

About Umbra Applied Technologies Group, Inc.

The firm is located in Tampa Florida and focuses on advanced technologies across many disciplines. UAT Group is a holding company with interests in both public and private companies during the early stages of development as well as growth stages of companies with a synergistic business model to UAT Group subsidiaries.

For more information visit www.uatgroup.com

Investor and Media Contact: UAT Group at [e-mail]
https://ca.finance.yahoo.com/news/uat-group-strategic-partner-nextcast-120000916.html

UAT Group Inc. Acquires Additional 6% of Next Casting Technologies

Tampa, FL, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Umbra Applied Technologies Group, Inc. (OTC Pink: UATG) announced today that it has purchased an additional 6% of the Austin, Texas based medical company Next Casting Technologies.

Chief Executive Officer, Alex Umbra commented: "Increasing our equity position to 26% will further expand our value position and ROI. Continuing to expand on this partnership is in keeping with our growth through acquisition strategy and is a core principle of our business model”.

Next Casting Technologies (NCT), is a research and design-centric, biomedical technology company, with an expanding portfolio of intellectual property. The NCT team of experienced engineers, designers, certi?cation experts and business professionals combine advanced design with paradigm shifting technology engineered to disrupt and transform the casting, bracing and splinting space.

The current SmartCast technology is now ready for commercial production. Next Cast anticipates production molds to be delivered to manufacturing site within the next 60 days. Production is scheduled to begin in Q3 of this year, with the first unit being delivered to customers across the United States in November of this year.

The global orthopedic casting, splinting, braces and support market was valued at US $4.6 billion in 2015 and is expected to reach US $7.9 billion by 2024, at a CAGR of 6.4%. Next Casting Technologies has projected its first-year revenues to be $16.1M once it launches, with a five-year evaluation in excess of $80M.

Next Cast expects to file additional patents ahead of the Q3 launch, with several patents supporting next generation casts currently under development.

For more information about Next Cast go here: https://www.nextorthocast.com/

About Umbra Applied Technologies Group, Inc.:

The firm is located in Tampa Florida and focuses on advanced technologies across many disciplines. UAT Group is a holding company with interests in both public and private companies during the early stages of development as well as growth stages of companies with a synergistic business model to UAT Group subsidiaries.

For more information, visit www.uatgroup.com

Investor and Media Contact: UAT Group at [e-mail]
https://www.otcmarkets.com/stock/UATG/news/UAT-Group-Inc-Acquires-Additional-6-of-Next-Casting-Technologies?id=318176

Delta Variant Testing Device Developed by UAT Group Affiliate, Bacter Scientific

Austin, TX, July 22, 2021 (GLOBE NEWSWIRE) -- Bacter Scientific, Inc. a medical research company and its strategic partner Umbra Applied Technologies Group, Inc (OTC Pink: UATG), announced today that its hand-held Covid-19 and virus test unit dubbed Novi, will be delivered with the capability to test for variants.

Genetic variants of SARS-CoV-2 have been emerging and circulating around the world throughout the COVID-19 pandemic. Viruses constantly change through mutation. A variant has one or more mutations that differentiate it from other variants in circulation. As expected, multiple variants of SARS-CoV-2 have been documented in the United States and globally throughout this pandemic. To inform local outbreak investigations and understand national trends, scientists compare genetic differences between viruses to identify variants and how they are related to each other.

Bacter Scientific, CEO and lead designer stated, “Like all viruses, the coronavirus takes control of cells in its host, and it uses those cells to print more copies of itself. Each new copy of a virus contains tiny copying errors or variations in its genome which is what is referred to as a variant. Most of these variations are insignificant, but occasionally, one offers a significant evolutionary advantage. It might be harder for immune systems to detect. It might be more transmissible. Sometimes and quite rapidly, it can become the dominant strain. This can render existing testing processes obsolete, and this is where Novi becomes the only real solution for infectious screening”.

The hand-held portable Novi testing unit fits in the palm of your hand and is capable of delivering fast, accurate results in minutes using loop-mediated isothermal ampli?cation (LAMP) based technology. The unit tests patient saliva in disposable tubes that can be used to screen for various respiratory dwelling viruses and their variants such as COVID-19, MERS, TB, Zika Virus, Influenza variants, Human Metapneumovirus and many others.

LAMP reactions rapidly generate large quantities of amplified material when pathogenic bacteria/viruses are present in a patient sample delivering results in minutes exceeding standard PCR testing times which can take days not minutes. Due to the large number of binding sites on target DNA/RNA, the LAMP method is inherently highly specific. The isothermal nature of the reaction means that no thermal cycling is required, facilitating the use of a hand-held, portable, analyzer like Bacter Scientifics Novi device.

Chief Executive Officer of UAT Group Alex Umbra commented, “It is our assessment that LAMP technology will emerge as the alternative molecular detection method for the detection of SARS-CoV-2 and in fact, we believe there is clinical evidence that supports its use as the preferred primary screening technology now that there is a hand-held unit capable of delivering faster and more accurate results with significant reliability. As a strategic partner of Bacter Scientific we will continue to support the further development of this technology so that we can contribute to this crisis in a positive and meaningful way”.

WHO Guidelines recommend the use of molecular amplification tests for the detection of COVID-19 due to their superior sensitivity, specificity, and speed. LAMP technology is clinically proven to provide highly accurate and specific results and aligns with the World Health Organization recommendations as a NAAT detection method for infectious diseases (see link to report below)

The US Department of Health and Human Services (HHS) established a SARS-CoV-2 Interagency Group (SIG) to improve coordination among the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), Food and Drug Administration (FDA), Biomedical Advanced Research and Development Authority (BARDA), and Department of Defense (DoD). This interagency group is focused on the rapid characterization of emerging variants and actively monitors their potential impact on critical SARS-CoV-2 countermeasures, including vaccines, therapeutics, and diagnostics. Bacter Scientific is looking to coordinate with HHS, SIG, CDC, BARDA, DoD and NIH to deliver a highly nimble device that can assist in inter-agency coordination through its onboard reporting app built into its Novi testing unit.

Umbra further added, “LAMP provides a highly specific, low cost, portable test for pathogenic bacteria and/or viruses in minutes and while the foundational technology is not new, what is new is that capabilities only found in Novi. Novi is the only hand-held, portable, battery powered device with built-in redundancy, delivering the most accurate results of any testing device. We believe that this platform will bolster Federal agencies efforts and change the way we combat the spread of disease in the future”.

Viral mutations and variants in the United States are routinely monitored through sequence-based surveillance, laboratory studies, and epidemiological investigations. A US government SARS-CoV-2 Interagency Group (SIG) developed Variant Classifications that defines three classes of SARS-CoV-2 variants. Currently, there are 6 variants of interest, 4 variants of concern and 4 variants of consequence. There are no variants of consequence currently active in the continental United States.

For more information about Bacter Scientific, Inc. go here: http://bacterscientific.com

For more information, visit www.uatgroup.com

Investor and Media Contact: UAT Group at: [e-mail]

For link to World Health Organization report go here: https://apps.who.int/iris/bitstream/handle/10665/331501/WHO-COVID-19-laboratory-2020.5-eng.pdf?sequence=1&isAllowed=y

About Bacter Scientific, Inc.

The company is located in Austin, TX and is a medical device manufacturer and research company based in Austin, Texas specializing in the development of products that detect and prevent infection in clinical, commercial, industrial and residential environments

For more information, visit www.bacterscientific.com

https://ca.finance.yahoo.com/news/delta-variant-testing-device-developed-120000197.html

UAT Group Affiliate, H2O Processing Joins State of Colorado Water Initiative
https://ca.finance.yahoo.com/news/uat-group-affiliate-h2o-processing-120000641.html

UAT Group Affiliate, Bacter Scientific to File 510(k) While Awaiting EUA Approval
https://ca.finance.yahoo.com/news/uat-group-affiliate-bacter-scientific-120000998.html

UAT Group, Inc. Completes Bid to Acquire Orthopedic Implant Company
https://ca.finance.yahoo.com/news/uat-group-inc-completes-bid-124500009.html